Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the H.C. Wainwright Global Investment Conference, with a webcast presentation scheduled for May 24, 2022, at 7 a.m. ET. This on-demand presentation will be accessible through their website, allowing investors to catch up after the event as a replay will be available for 30 days.

The company focuses on developing therapies for cancer, particularly through their investigational treatment, entospletinib, targeting NPM1-mutated acute myeloid leukemia.

Positive

• Participation in the H.C. Wainwright Global Investment Conference may enhance visibility and investor interest.
• The webcast format allows for broader access to potential investors and stakeholders.
• Kronos Bio's focus on innovative cancer therapies positions it well in a growing market.

Negative

• None.

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright Global Investment Conference. An on-demand webcast of the presentation will be available on Tuesday, May 24, 2022, at 7 a.m. ET.

The webcast will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcast will be archived and available for 30 days following the event.

About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer and other serious diseases. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Company Contact:
Marni Kottle
Kronos Bio
650-900-3450
mkottle@kronosbio.com

Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com 

FAQ

When is the Kronos Bio presentation at the H.C. Wainwright Global Investment Conference?

The Kronos Bio presentation is scheduled for May 24, 2022, at 7 a.m. ET.

How can I access the webcast of the Kronos Bio conference presentation?

The webcast will be available on the Kronos Bio website in the Investors and Media section.

What is the focus of Kronos Bio's research?

Kronos Bio is dedicated to developing therapies for cancer, targeting dysregulated transcription factors.

What is entospletinib and its purpose?

Entospletinib is an investigational therapy targeting spleen tyrosine kinase for NPM1-mutated acute myeloid leukemia.

Where is Kronos Bio located?

Kronos Bio is based in San Mateo, California, with a research facility in Cambridge, Massachusetts.